Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes

Iowa medicaid 2: lapse of glycemic control on abrupt transition from insulin glargine to insulin detemir in type 2 diabetes mellitus

“…Moreover, in the long term, there are always several untoward consequences of weight gain, e.g. cardiovascular outcomes which could not be addressed in these short term studies [21][22][23][24][25][26]. Lack of severe hypoglycemic events noted in this study among both groups is not an unusual finding in subjects with type 2 Diabetes (2).…”

“…Lack of severe hypoglycemic events noted in this study among both groups is not an unusual finding in subjects with type 2 Diabetes (2). However, hypoglycemic events are likely to rise with a greater daily dose of insulin detemir used once daily and may be further exacerbated in subjects with twice daily administration because of induction of multiple daily insulin peaks in the circulation as documented in previous studies using other insulin's achieving peak concentrations [21][22][23][24][25][26].…”

“…Thus, use of detemir may adversely affect quality of life in the short term, since several studies have documented that higher the daily insulin dose, more frequent the daily injections and more the peaks of insulin during the day, greater is the occurrence of hypoglycemic events and greater is the weight gain [21][22][23][24][25][26]. Moreover, in the long term, there are always several untoward consequences of weight gain, e.g.…”

Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes

“…[40][41][42] Moreover, this regimen can effectively lower HbA 1c and postprandial hyperglycemia when compared with an optimized regimen of OADs. In the 26-week trial by Bebakar et al, 42 191 patients poorly controlled on one or two OADs were randomized to BIAsp 30 (0.2 U/kg/day) od before dinner in addition to their OADs, or to an optimized regimen of their existing OADs.…”

“…This allows us to examine the studies according to patient population: studies of insulin-naive patients initiating insulin with BIAsp 30, [35][36][37][38][39][40][41][42][43][44][45][46][47][48] and studies of patients switching existing insulin therapy to, or intensifying with, BIAsp 30.…”